169 related articles for article (PubMed ID: 8675325)
1. Deletion of purE attenuates Brucella melitensis infection in mice.
Crawford RM; Van De Verg L; Yuan L; Hadfield TL; Warren RL; Drazek ES; Houng HH; Hammack C; Sasala K; Polsinelli T; Thompson J; Hoover DL
Infect Immun; 1996 Jun; 64(6):2188-92. PubMed ID: 8675325
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte proliferative responses of goats vaccinated with Brucella melitensis 16M or a delta purE201 strain.
Olsen SC; Cheville NF; Stevens MG; Houng HH; Drazek ES; Hadfield TL; Warren RL; Hoover DL
Infect Immun; 1997 Jul; 65(7):2987-91. PubMed ID: 9199478
[TBL] [Abstract][Full Text] [Related]
3. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages.
Drazek ES; Houng HS; Crawford RM; Hadfield TL; Hoover DL; Warren RL
Infect Immun; 1995 Sep; 63(9):3297-301. PubMed ID: 7642258
[TBL] [Abstract][Full Text] [Related]
4. Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16M strain of Brucella melitensis.
Cheville NF; Olsen SC; Jensen AE; Stevens MG; Florance AM; Houng HS; Drazek ES; Warren RL; Hadfield TL; Hoover DL
Infect Immun; 1996 Jul; 64(7):2431-9. PubMed ID: 8698463
[TBL] [Abstract][Full Text] [Related]
5. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
[TBL] [Abstract][Full Text] [Related]
6. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.
Zhang J; Guo F; Chen C; Li Z; Zhang H; Wang Y; Zhang K; Du G; Li Y; Wang J; Jian T; Wang Z
Microbiol Immunol; 2013 Jul; 57(7):502-10. PubMed ID: 23647412
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge.
Arenas-Gamboa AM; Ficht TA; Kahl-McDonagh MM; Rice-Ficht AC
Infect Immun; 2008 Jun; 76(6):2448-55. PubMed ID: 18362129
[TBL] [Abstract][Full Text] [Related]
8. A Brucella melitensis high temperature requirement A (htrA) deletion mutant demonstrates a stress response defective phenotype in vitro and transient attenuation in the BALB/c mouse model.
Phillips RW; Elzer PH; Roop RM II
Microb Pathog; 1995 Nov; 19(5):227-84. PubMed ID: 8778563
[TBL] [Abstract][Full Text] [Related]
9. Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis.
Mense MG; Van De Verg LL; Bhattacharjee AK; Garrett JL; Hart JA; Lindler LE; Hadfield TL; Hoover DL
Am J Vet Res; 2001 Mar; 62(3):398-405. PubMed ID: 11277206
[TBL] [Abstract][Full Text] [Related]
10. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection.
Wang Y; Bai Y; Qu Q; Xu J; Chen Y; Zhong Z; Qiu Y; Wang T; Du X; Wang Z; Yu S; Fu S; Yuan J; Zhen Q; Yu Y; Chen Z; Huang L
Vet Microbiol; 2011 Aug; 151(3-4):354-62. PubMed ID: 21530111
[TBL] [Abstract][Full Text] [Related]
11. TceSR two-component regulatory system of Brucella melitensis 16M is involved in invasion, intracellular survival and regulated cytotoxicity for macrophages.
Li Z; Fu Q; Wang Z; Li T; Zhang H; Guo F; Wang Y; Zhang J; Chen C
Lett Appl Microbiol; 2015 Jun; 60(6):565-71. PubMed ID: 25721466
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of in murine model, of an improved live-vaccine candidate against brucellosis from to Brucella melitensis vjbR deletion mutant.
Li Z; Wang S; Zhang H; Xi L; Zhang J; Zhang X; Zhou Q; Yi J; Li M; Zhang W; Zhang J
Microb Pathog; 2018 Nov; 124():250-257. PubMed ID: 30149131
[TBL] [Abstract][Full Text] [Related]
13. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.
Bhattacharjee AK; Izadjoo MJ; Zollinger WD; Nikolich MP; Hoover DL
Infect Immun; 2006 Oct; 74(10):5820-5. PubMed ID: 16988260
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli.
Bowden RA; Cloeckaert A; Zygmunt MS; Dubray G
J Med Microbiol; 1998 Jan; 47(1):39-48. PubMed ID: 9449948
[TBL] [Abstract][Full Text] [Related]
15. A study on the use of male animal models for developing a live vaccine for brucellosis.
Izadjoo MJ; Mense MG; Bhattacharjee AK; Hadfield TL; Crawford RM; Hoover DL
Transbound Emerg Dis; 2008 May; 55(3-4):145-51. PubMed ID: 18405337
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of defined Brucella melitensis wboA mutants.
Nikolich MP; Warren RL; Lindler LE; Izadjoo MJ; Hoover DL
Vaccine; 2010 Oct; 28 Suppl 5():F12-6. PubMed ID: 20362622
[TBL] [Abstract][Full Text] [Related]
17. Live mucosal vaccination stimulates potent protection
Goodwin ZI; Yang X; Hoffman C; Pascual DW
Front Immunol; 2022; 13():995327. PubMed ID: 36263034
[TBL] [Abstract][Full Text] [Related]
18. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.
Bhattacharjee AK; Van de Verg L; Izadjoo MJ; Yuan L; Hadfield TL; Zollinger WD; Hoover DL
Infect Immun; 2002 Jul; 70(7):3324-9. PubMed ID: 12065469
[TBL] [Abstract][Full Text] [Related]
19. Brucella melitensis 16M: characterisation of the galE gene and mouse immunisation studies with a galE deficient mutant.
Petrovska L; Hewinson RG; Dougan G; Maskell DJ; Woodward MJ
Vet Microbiol; 1999 Feb; 65(1):21-36. PubMed ID: 10068125
[TBL] [Abstract][Full Text] [Related]
20. Nramp1 is not a major determinant in the control of Brucella melitensis infection in mice.
Guilloteau LA; Dornand J; Gross A; Olivier M; Cortade F; Vern YL; Kerboeuf D
Infect Immun; 2003 Feb; 71(2):621-8. PubMed ID: 12540538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
